Get started
Author

Michelle Byrtek

Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
2015 · Carla Casulo, Michelle Byrtek, et al. · Journal of Clinical Oncology · 853
Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)
2015 · Nina D. Wagner-Johnston, Brian K. Link, et al. · Blood · 220
PDF
Effectiveness of First-Line Management Strategies for Stage I Follicular Lymphoma: Analysis of the National LymphoCare Study
2012 · Jonathan W. Friedberg, Michelle Byrtek, et al. · Journal of Clinical Oncology · 180
Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma
2016 · Thomas Powles, Mark R. Lackner, et al. · Journal of Clinical Oncology · 133
Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices
2012 · A.K. Nooka, C. Nabhan, et al. · Annals of Oncology · 98
PDF
Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma‐related mortality in elderly follicular lymphoma in the United States
2015 · Chadi Nabhan, Michelle Byrtek, et al. · British Journal of Haematology · 68
Outcomes following watchful waiting for stage II – IV follicular lymphoma patients in the modern era
2016 · Loretta J. Nastoupil, Rajni Sinha, et al. · British Journal of Haematology · 60
PDF
Racial differences in presentation and management of follicular non‐Hodgkin lymphoma in the United States
2012 · Chadi Nabhan, Michelle Byrtek, et al. · Cancer · 44
Abstract P6-12-03: Meta-Analysis of Patients with Triple-Negative Breast Cancer (TNBC) from Three Randomized Trials of First-Line Bevacizumab (BV) and Chemotherapy Treatment for Metastatic Breast Cancer (MBC)
2010 · J O'Shaughnessy, G Romieu, et al. · Cancer Research · 41
The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States
2014 · Loretta J. Nastoupil, Rajni Sinha, et al. · Cancer · 35
PDF
Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States
2014 · Loretta J. Nastoupil, Rajni Sinha, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 26
Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: Results of the National LymphoCare Study
2013 · Peter Martin, Michelle Byrtek, et al. · Cancer · 23
PDF
A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT).
2014 · Thomas Powles, Stephane Oudard, et al. · Journal of Clinical Oncology · 19
A Comparison of the Effectiveness of First-Line Chemoimmunotherapy Regimens for Follicular Lymphoma (FL) Used in the United States
2011 · Loretta Nastoupil, Rajni Sinha, et al. · Blood · 15
[18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice
2016 · Ida Wong-Sefidan, Michelle Byrtek, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 10
PDF
Early Relapse Of Follicular Lymphoma After R-CHOP Uniquely Defines Patients At High Risk For Death: An Analysis From The National Lymphocare Study
2013 · Carla Casulo, Michelle Byrtek, et al. · Blood · 8
Examining the Outcomes of Watchful Waiting (WW) Among US Patients with Advanced Stage Follicular Lymphoma (FL)
2011 · Rajni Sinha, Michelle Byrtek, et al. · Blood · 8
Development of a Predictive Model for Cytokine Release Syndrome to Inform Risk Stratification and CRS Management Following Immunotherapy
2021 · Krishna V. Komanduri, Anton Belousov, et al. · Blood · 7
Second-line therapy in follicular lymphoma in the United States: Report of NLCS observational study.
2011 · B. K. Link, T. P. Miller, et al. · Journal of Clinical Oncology · 5
STEAM: A randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) versus FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).
2014 · Johanna C. Bendell, Benjamin R. Tan, et al. · Journal of Clinical Oncology · 4
A Simulation Analysis to Evaluate the Effect of Prospective Biomarker Testing on Progression-Free Survival (PFS) in DLBCL
2017 · Edith Szafer‐Glusman, Juan Liu, et al. · Blood · 3
Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma
2019 · Aparna Raval, Hearn Jay Cho, et al. · Blood · 2
Abstract A03: Comprehensive predictive biomarker evaluation in two phase II clinical trials of the PI3K/mTOR inhibitor GDC-0980 in metastatic renal cell carcinoma and advanced endometrial cancer
2015 · Jill M. Spoerke, Vicky Makker, et al. · Molecular Cancer Therapeutics · 2
Characteristics and Effectiveness of Rituximab (R) Maintenance Regimens Among US Patients Diagnosed with Follicular Lymphoma (FL) 2004–2007,
2011 · Loretta Nastoupil, Rajni Sinha, et al. · Blood · 2
Does An Anthracycline Make a Difference for Follicular Lymphoma (FL) Grade 3? Patterns of Care and Treatment Outcomes of Grade 3 FL From the National LymphoCare Study (NLCS)
2010 · Christopher R Flowers, Michael Taylor, et al. · Blood · 2
Works count: 36
Citation count: 1,874
H-index: 14
I10-index: 15
Year
Topic
Type